Carlyle Group Inc. Files SC 13D/A for Soleno Therapeutics

TL;DR

Carlyle Group just filed a 13D/A on Soleno Therapeutics. Watch this space.

AI Summary

On October 21, 2024, Carlyle Group Inc. filed an SC 13D/A, indicating a change in its beneficial ownership of Soleno Therapeutics Inc. The filing details a group of entities, including Carlyle Genesis UK LLC and Carlyle Investment Management L.L.C., as part of the reporting group. The specific percentage of ownership or dollar amount involved in this change was not detailed in the provided header information.

Why It Matters

This filing signals a potential shift in control or significant investment by Carlyle Group in Soleno Therapeutics, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate significant strategic moves by large investors, potentially leading to volatility.

Key Players & Entities

• Carlyle Group Inc. (company) — Filer of the SC 13D/A
• Soleno Therapeutics Inc (company) — Subject company of the filing
• Carlyle Genesis UK LLC (company) — Group member of the filer
• Carlyle Investment Management L.L.C. (company) — Group member of the filer
• Capnia, Inc. (company) — Former name of Soleno Therapeutics Inc.

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $53.38 — Per Share October 14, 2024 107,810 $53.38 to $55.24 $54.4430 October 15, 2024
• $55.24 — October 14, 2024 107,810 $53.38 to $55.24 $54.4430 October 15, 2024 121,159
• $54.4430 — 14, 2024 107,810 $53.38 to $55.24 $54.4430 October 15, 2024 121,159 $53.415 t
• $53.415 — $54.4430 October 15, 2024 121,159 $53.415 to $55.00 $54.2023 October 16, 2024
• $55.00 — October 15, 2024 121,159 $53.415 to $55.00 $54.2023 October 16, 2024 113,899
• $54.2023 — 15, 2024 121,159 $53.415 to $55.00 $54.2023 October 16, 2024 113,899 $53.95 to
• $53.95 — $54.2023 October 16, 2024 113,899 $53.95 to $55.00 $54.5578 October 17, 2024
• $54.5578 — 16, 2024 113,899 $53.95 to $55.00 $54.5578 October 17, 2024 156,179 $53.00 to
• $53.00 — $54.5578 October 17, 2024 156,179 $53.00 to $54.05 $53.4632 (d) None. (e)
• $54.05 — October 17, 2024 156,179 $53.00 to $54.05 $53.4632 (d) None. (e) As of Oc
• $53.4632 — 17, 2024 156,179 $53.00 to $54.05 $53.4632 (d) None. (e) As of October 17, 2

Filing Documents

• d890003dsc13da.htm (SC 13D/A) — 184KB
• 0001193125-24-240444.txt ( ) — 186KB

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 40,142,314 shares of Common Stock, which includes (i) 38,871,594 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Issuers quarterly report on Form 10-Q filed on August 7, 2024, (ii) 22,913 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof, (iii) 1,213,758 shares of Common Stock underlying the Prefunded Warrants, all of which are currently exercisable and (iv) 34,049 shares of Common Stock underlying a portion of the March 2022 Warrants, which are currently exercisable. Reporting Person Amount beneficially owned Percent of class Sole power to vote or to direct the vote Shared power to vote or to direct the vote Sole power to dispose or to direct the disposition Shared power to dispose or to direct the disposition The Carlyle Group Inc. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 Carlyle Holdings I GP Inc. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 Carlyle Holdings I GP Sub L.L.C. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 Carlyle Holdings I L.P. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 CG Subsidiary Holdings L.L.C. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 TC Group, L.L.C. 2,003,101 4.99 % 0 2,003,101 0 2,003,101 Carlyle Investment Management L.L.C. 2,003,101 4.99 % 0 2,003,101 0 2,003,1

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : October 21, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CUSIP No. 834203200 13D Page 15 of 15 pages Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures VII LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory

View Full Filing

View this SC 13D/A filing on SEC EDGAR